Welcome to our dedicated page for Baxter Intl news (Ticker: BAX), a resource for investors and traders seeking the latest updates and insights on Baxter Intl stock.
Baxter International Inc. reports news on its global medtech business, which supplies hospitals, physician offices and other care settings with connected solutions, medical devices and advanced injectable technologies. Company updates commonly cover results from continuing operations following the Kidney Care divestiture, portfolio activity in infusion therapies and platforms, surgical tables, smart stretchers, patient-support systems, monitoring tools, and hemostatic and sealing agents.
Baxter announcements also address product introductions such as the IV Verify Line Labeling System, conference showcases for Global Surgical Solutions, Advanced Surgery and Patient Support Systems, annual-meeting matters, executive finance leadership, and foundation partnerships tied to healthcare settings.
Summary not available.
Summary not available.
Baxter International Inc. (NYSE:BAX) reported first-quarter 2023 revenue of $3.65 billion, a 2% decrease year-over-year on a reported basis but a 2% increase on a constant currency basis. U.S. GAAP earnings per share (EPS) were $0.09, while adjusted EPS was $0.59. For 2023, Baxter anticipates sales growth of 1% to 2% and U.S. GAAP EPS between $1.16 and $1.31, with adjusted EPS between $2.85 and $3.00. Key drivers for sales included Advanced Surgery and Pharmaceuticals, though declines were noted in Acute Therapies and Patient Support Systems. The company is also advancing a strategic spinoff of its Kidney Care segment, expected to occur by July 2024. Innovation efforts include launching the Novum IQ and ExactaMix Pro systems, aimed at enhancing patient care and operational efficiency.
Baxter International Inc. (NYSE:BAX) will present at the BofA Securities 2023 Health Care Conference on May 9, 2023. Chief Financial Officer Jay Saccaro is scheduled to speak at 1:00 p.m. Eastern Time. A live webcast of the presentation can be accessed on www.baxter.com and will remain available for replay until November 5, 2023.
Baxter provides critical care, kidney care, and surgical products that are vital for patients and caregivers in over 100 countries. With a history spanning more than 90 years, the company continues to innovate in healthcare solutions, enhancing patient care and supporting providers.
Baxter International Inc. (NYSE:BAX) has announced a conference call scheduled for April 27, 2023, at 7:30 a.m. Central Time to discuss its first-quarter 2023 financial results. Participants can pre-register for the call via the provided link or access it through Baxter's website. The call will be recorded and copyrighted by Baxter, with restrictions on rebroadcasting without permission. Baxter is recognized for its extensive portfolio in diagnostic, critical care, kidney care, nutrition, and surgical products, emphasizing its commitment to innovation and patient care over the past 90 years.
Baxter International Inc. (NYSE:BAX) has launched ZOSYN (piperacillin and tazobactam) Injection in the U.S., expanding its anti-infective portfolio. The ZOSYN premix is designed to treat various infections and is packaged in Baxter’s proprietary Galaxy containers, ensuring patient safety by simplifying medication preparation and improving operational efficiency. Available in multiple dosages (2.25 g, 3.375 g, and 4.5 g), this ready-to-use formulation aims to reduce contamination risks. Baxter emphasizes that ZOSYN is a significant addition, addressing critical healthcare needs while advancing patient care.
Baxter International Inc. (NYSE:BAX) introduced several innovative surgical solutions at the AORN Global Surgical Conference & Expo 2023 held from April 1-4, 2023. Key products include a new conductive Patient Warming System that minimizes risks linked to forced air warming and is designed to maintain body temperature effectively. The Helux Pro Connected Surgical Light enhances visibility during procedures with deep cavity lighting and a 4K camera. Additionally, the Floseal + Recothrom hemostat, utilizing recombinant thrombin, offers a faster preparation time and eliminates reliance on human blood products. These advancements aim to enhance patient care and efficiency in surgical settings.
Baxter International Inc. (NYSE:BAX) will hold its 2023 Annual Meeting of Stockholders virtually on May 2, 2023, at 9 a.m. Central Time. Online access begins at 8:30 a.m.. Stockholders are encouraged to vote their shares beforehand through proxy materials as in-person attendance is not allowed. Questions can be submitted in advance from April 28 to May 1 or live during the meeting. Those wishing to join as guests can listen-only, without voting or asking questions. Baxter emphasizes its long-standing commitment to innovation in healthcare, serving millions worldwide.
Baxter International Inc. (NYSE:BAX) declared a quarterly cash dividend of $0.29 per share, payable on April 3, 2023, to shareholders of record as of February 24, 2023. This indicates an annual dividend rate of $1.16 per share. The company has a rich history of over 90 years in providing healthcare solutions across more than 100 countries. This dividend declaration reflects Baxter's commitment to returning value to its shareholders amidst a stable operational strategy.
Baxter International reported a Q4 2022 sales increase of 11% to $3.9 billion, with 18% growth for the full year at $15.1 billion. Fourth-quarter U.S. GAAP diluted EPS was $0.36, adjusted EPS $0.88. Full-year U.S. GAAP diluted loss per share was ($4.83), adjusted EPS at $3.50, down 3% year-over-year. The company faces ongoing macroeconomic challenges, leading to plans for a spinoff of its Renal Care and Acute Therapies businesses. Baxter’s cost reduction initiatives aim to save over $300 million in 2023, with a workforce reduction of less than 5%.